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Case Reports
Cyclosporin induced fatal rhabdomyolysis in a Young Patient with Acquired
Aplastic Anemia: a Case Report
M. Usman, S. N. Adil, G. N. Kakepoto, M. Khurshid
Department of Pathology, The Aga Khan University Hospital, Karachi..
Introduction
Cyclosporin is used as an immunosuppressive
agent in the management of a variety of autoimmune
disorders1 and in patients of organ transplant to sup-
press host immunity and prevent rejection.2 It is now
well established that acquired aplastic anemia is sec-
ondary to immune mediated destruction of stem cells
in the bone marrow3 and hence Cyclosporin is used as
a first line immunosuppressive drug alone or in combi-
nation with anti lymphocyte globulin in the manage-
ment of aplastic anemia.1 Rhabdomyolysis is a rare
side effect of Cyclosporin.4 Here we describe a case of
fatal rhabdomyolysis in a young patient who received
cyclosporin for treatment of aplastic anemia.
Case Report
A sixteen years old male presented to the hema-
tology outpatient with history of fever and increasing
pallor since two weeks. There was no significant past
medical, drug or family history. On examination, he
was grossly pale. Petechial hemorrhages were evident
on both legs and feet. Other general and systemic
examination was unremarkable. Subsequently, a com-
plete blood count, reticulocyte count, bone marrow and
trephine were carried out which was consistent with
the diagnosis of severe aplastic anemia according to
the Camitta classification.5 Hepatitis B surface antigen
was non-reactive. Chromosomal studies were normal
while Ham's test was negative.
Various treatment options were discussed and
the patient opted for immunosuppressive therapy. He
was given injection anti lymphocyte globulin 10mg/kg
daily intravenously for five days and injection methyl
prednisolone 2mg/kg intravenously for four days. On
fifth day of the treatment, he was started on oral
Cyclosporin 5mg/kg daily. After just three doses of
cyclosporin, he developed severe pain in both calf
muscles. 
Examination revealed a heart rate of 120 per minute,
temperature 38oC and blood pressure 105/65 mm Hg. There
was bilateral calf muscles swelling and marked tenderness
with a complete functional disability of both lower limbs.
Skin color was normal. Pedal pulse was palpable in both
lower limbs. Laboratory investigations done at that time
revealed hemoglobin 7.3gm/dl, white cell count 700/cumm,
platelet count 15,000/cumm, prothrombin time 18 seconds
(control 13 seconds), activated partial thrombin time 42 sec-
onds (control 30 seconds),  blood urea nitrogen 27mg/dl (6-
16), serum creatinine 3.1mg/dl (0.8-1.3), uric acid 7.9mg/dl
(4.1-8.0), total bilirubin 3.8mg/dl (0.2-1.2), SGPT 167i.u. /L
(0-55), creatine phosphokinase 7451i.u. (17-176), serum
myoglobin 6150ug/L (upto 70). Ultrasound Doppler of both
lower limbs revealed no evidence of deep venous thrombo-
sis. Ultrasound of the abdomen was within normal limits.
He was admitted to the hospital. Cyclosporin was
stopped. He was started on intravenous fluids along with
empiric antibiotics. But his condition deteriorated and he
developed anuria. Subsequent laboratory investigations
revealed a further rise in serum creatinine to 4.2mg/dl and
serum creatine phosphokinase was 3407i.u. (17-76). He
developed tachycardia, tachypnea and hypotension after 24
hours of admission. Oxygen saturation dropped and he was
resuscitated and intubated, but could not be revived and
expired.
Discussion
Cyclosporin is used as an immunosuppressive that
inhibits interleukin-2 production by T lymphocytes and pre-
vents the expansion of cytotoxic T cells. It is commonly used
in patients of acquired aplastic anemia, post allogenic bone
marrow transplant graft  versus host disease, other organ trans-
plant patients and in many autoimmune disorders.6 Apartfrom
immunosuppression, Cyclosporin may affect skeletal mus-
cles. Most of the cases suggest that Cyclosporin associated
muscular disorders have two patterns. First is the myopathy
without myolysis. In this case muscle enzymes are usually
normal with non-specific myopathy on muscle biopsy,
if performed. This type of myopathy appears to be dose
dependent and symptoms usually improve as soon as
the drug is stopped.7 The second pattern is that of rhab-
domyolysis and most of the time it occurs from interac-
tion with other drugs notably the statins8 and
cholchicine.9 The pathophysiology of drug interaction
has not been established.
However, Cyclosporin alone can induce rhab-
domyolysis as we have seen in this case and to our
knowledge has not been reported in a patient of aplas-
tic anemia. Previously, Cyclosporin induced fatal rhab-
domyolysis was seen in individuals receiving statins
and in a patient of post bone marrow transplant .4
Conclusion
Our report concludes that myopathy and hab-
domyolysis are well-established rare side effects of
cyclosporin. As the indications for the use of
cyclosporine is increasing, we recommend a close clin-
ical surveillance along with laboratory parameters in
patients on cyclosporin.  
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